Cargando…
Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients
OBJECTIVES: Hepatic hydrothorax (HH) is a predictor of poor survival in cirrhosis patients. However, whether HH increases the mortality risk of cirrhosis patients treated with transjugular intrahepatic portosystemic shunt (TIPS) is unknown. Our objective was to evaluate the influence of HH on the su...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121519/ https://www.ncbi.nlm.nih.gov/pubmed/36576548 http://dx.doi.org/10.1007/s00330-022-09357-3 |
_version_ | 1785029387316363264 |
---|---|
author | Gou, Xiaoyuan Jia, Wenyuan He, Chuangye Yuan, Xulong Niu, Jing Xu, Jiao Han, Na Zhu, Ying Wang, Wenlan Tie, Jun |
author_facet | Gou, Xiaoyuan Jia, Wenyuan He, Chuangye Yuan, Xulong Niu, Jing Xu, Jiao Han, Na Zhu, Ying Wang, Wenlan Tie, Jun |
author_sort | Gou, Xiaoyuan |
collection | PubMed |
description | OBJECTIVES: Hepatic hydrothorax (HH) is a predictor of poor survival in cirrhosis patients. However, whether HH increases the mortality risk of cirrhosis patients treated with transjugular intrahepatic portosystemic shunt (TIPS) is unknown. Our objective was to evaluate the influence of HH on the survival of cirrhosis patients after TIPS. METHODS: Cirrhosis patients with portal hypertension complications were selected from a prospective database of consecutive patients treated with TIPS in Xijing Hospital from January 2015 to June 2021. Cirrhosis patients with HH were treated as the experimental group. A control group of cirrhosis patients without HH was created using propensity score matching. Survival after TIPS and the related risk factors were analysed. RESULTS: There were 1292 cirrhosis patients with portal hypertension complications treated with TIPS, among whom 255 patients had HH. Compared with patients without HH, patients with HH had worse liver function (MELD, 12 vs. 10, p < 0.001), but no difference in survival after TIPS was observed. After propensity score matching, 243 patients with HH and 243 patients without HH were enrolled. There was no difference in cumulative survival between patients with and without HH. Cox regression analysis showed that HH was not associated with survival after TIPS, and main portal vein thrombosis (> 50%) was a prognostic factor of long-term survival after TIPS in cirrhosis patients (hazard ratio, 1.386; 95% CI, 1.030–1.865, p = 0.031). CONCLUSION: Hepatic hydrothorax does not increase the risk of death after TIPS in cirrhosis patients. KEY POINTS: • Hepatic hydrothorax is a decompensated event of cirrhosis and increases the risk of death. • Hepatic hydrothorax is associated with worse liver function. • Hepatic hydrothorax does not increase the mortality of cirrhosis treated with TIPS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-022-09357-3. |
format | Online Article Text |
id | pubmed-10121519 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-101215192023-04-23 Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients Gou, Xiaoyuan Jia, Wenyuan He, Chuangye Yuan, Xulong Niu, Jing Xu, Jiao Han, Na Zhu, Ying Wang, Wenlan Tie, Jun Eur Radiol Vascular-Interventional OBJECTIVES: Hepatic hydrothorax (HH) is a predictor of poor survival in cirrhosis patients. However, whether HH increases the mortality risk of cirrhosis patients treated with transjugular intrahepatic portosystemic shunt (TIPS) is unknown. Our objective was to evaluate the influence of HH on the survival of cirrhosis patients after TIPS. METHODS: Cirrhosis patients with portal hypertension complications were selected from a prospective database of consecutive patients treated with TIPS in Xijing Hospital from January 2015 to June 2021. Cirrhosis patients with HH were treated as the experimental group. A control group of cirrhosis patients without HH was created using propensity score matching. Survival after TIPS and the related risk factors were analysed. RESULTS: There were 1292 cirrhosis patients with portal hypertension complications treated with TIPS, among whom 255 patients had HH. Compared with patients without HH, patients with HH had worse liver function (MELD, 12 vs. 10, p < 0.001), but no difference in survival after TIPS was observed. After propensity score matching, 243 patients with HH and 243 patients without HH were enrolled. There was no difference in cumulative survival between patients with and without HH. Cox regression analysis showed that HH was not associated with survival after TIPS, and main portal vein thrombosis (> 50%) was a prognostic factor of long-term survival after TIPS in cirrhosis patients (hazard ratio, 1.386; 95% CI, 1.030–1.865, p = 0.031). CONCLUSION: Hepatic hydrothorax does not increase the risk of death after TIPS in cirrhosis patients. KEY POINTS: • Hepatic hydrothorax is a decompensated event of cirrhosis and increases the risk of death. • Hepatic hydrothorax is associated with worse liver function. • Hepatic hydrothorax does not increase the mortality of cirrhosis treated with TIPS. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00330-022-09357-3. Springer Berlin Heidelberg 2022-12-28 2023 /pmc/articles/PMC10121519/ /pubmed/36576548 http://dx.doi.org/10.1007/s00330-022-09357-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Vascular-Interventional Gou, Xiaoyuan Jia, Wenyuan He, Chuangye Yuan, Xulong Niu, Jing Xu, Jiao Han, Na Zhu, Ying Wang, Wenlan Tie, Jun Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients |
title | Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients |
title_full | Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients |
title_fullStr | Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients |
title_full_unstemmed | Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients |
title_short | Hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients |
title_sort | hepatic hydrothorax does not increase the risk of death after transjugular intrahepatic portosystemic shunt in cirrhosis patients |
topic | Vascular-Interventional |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10121519/ https://www.ncbi.nlm.nih.gov/pubmed/36576548 http://dx.doi.org/10.1007/s00330-022-09357-3 |
work_keys_str_mv | AT gouxiaoyuan hepatichydrothoraxdoesnotincreasetheriskofdeathaftertransjugularintrahepaticportosystemicshuntincirrhosispatients AT jiawenyuan hepatichydrothoraxdoesnotincreasetheriskofdeathaftertransjugularintrahepaticportosystemicshuntincirrhosispatients AT hechuangye hepatichydrothoraxdoesnotincreasetheriskofdeathaftertransjugularintrahepaticportosystemicshuntincirrhosispatients AT yuanxulong hepatichydrothoraxdoesnotincreasetheriskofdeathaftertransjugularintrahepaticportosystemicshuntincirrhosispatients AT niujing hepatichydrothoraxdoesnotincreasetheriskofdeathaftertransjugularintrahepaticportosystemicshuntincirrhosispatients AT xujiao hepatichydrothoraxdoesnotincreasetheriskofdeathaftertransjugularintrahepaticportosystemicshuntincirrhosispatients AT hanna hepatichydrothoraxdoesnotincreasetheriskofdeathaftertransjugularintrahepaticportosystemicshuntincirrhosispatients AT zhuying hepatichydrothoraxdoesnotincreasetheriskofdeathaftertransjugularintrahepaticportosystemicshuntincirrhosispatients AT wangwenlan hepatichydrothoraxdoesnotincreasetheriskofdeathaftertransjugularintrahepaticportosystemicshuntincirrhosispatients AT tiejun hepatichydrothoraxdoesnotincreasetheriskofdeathaftertransjugularintrahepaticportosystemicshuntincirrhosispatients |